Pfizer-BioNTech Eye Clearance of Omicron Booster for All Ages

August 23, 2022

2 minute read


Source/Disclosures


Disclosures: Bourla is employed by Pfizer. Sahin is employed by BioNTech.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

After seeking emergency use authorization for their omicron-adapted COVID-19 vaccine in people ages 12 and older, Pfizer and BioNTech said Tuesday they are also working with the FDA to bring a recall. to young children.

On Monday, the companies announced that they had completed an EUA submission for the booster dose of the bivalent COVID-19 vaccine adapted omicron BA.4/BA.5 for people aged 12 and older.



Draw of Pfizer bottles
Pfizer and BioNTech have asked the FDA to authorize a COVID-19 booster shot containing the omicron variant. Source: Adobe Stock.

The application included clinical data of the companies’ omicron BA.1-adapted bivalent vaccine – which they say elicited a “superior immune response” against the BA.1 variant compared to the current vaccine – and preclinical data and manufacturing of the companies’ bivalent vaccine. omicron BA.4/BA.5 adapted vaccine.

The bivalent vaccine targets both the BA.4 and BA.5 subvariants of omicron and the original SARS-CoV-2 spike protein.

In June, the FDA told vaccine makers they should add a spike protein component for both omicron subvariants to their existing vaccines to create bivalent boosters.

“The agility of the mRNA platform, coupled with extensive clinical experience with the Pfizer-BioNTech COVID-19 vaccine, has enabled us to develop, test and manufacture updated, high-quality vaccines that align with strains in circulation at an unprecedented rate,” said the Pfizer president. and CEO albert BourlaDVM, PhD, said in a statement.

“Having rapidly ramped up production, we are able to immediately begin distribution of omicron BA.4/BA.5 bivalent boosters, if authorized, to help protect individuals and families as we prepare for power surges. fall and winter potential,” Bourla said.

The companies announced additional data on Tuesday from a Phase 2/3 trial that showed their three doses, 3 µg The vaccine was 75.8% effective in preventing COVID-19 in children aged 6 months to 23 months (95% CI, 9.7% to 94.7%) and 71.8% effective ( 95% CI, 28.6% to 89.4%) for preventing COVID-19 in children 2-4 years old.

The pediatric vaccine has already been authorized for children aged 6 months to 4 years.

“While these results confirm that three 3µg doses of our COVID-19 vaccine provide young children with a high level of protection at a time when the omicron BA.2 strain was widespread with a favorable safety profile, we are also developing an omicron BA.4/BA.5 suitable bivalent vaccine in this age group to treat these sublines. CEO and co-founder of BioNTech Ugur Sahin, medical doctor, said in a statement.

The companies said they were “working with the FDA to prepare an EUA application for a bivalent vaccine suitable for 0 micron BA.4/BA.5 in children 6 months to 11 years of age.”

References:

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months to 4 Years. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-covid-19-vaccine-data. Published August 23, 2022. Accessed August 23, 2022.

Pfizer and BioNTech submit an application to the U.S. FDA for emergency use authorization of the adapted bivalent COVID-19 vaccine omicron BA.4/BA.5. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-use. Published August 22, 2022. Accessed August 23, 2022.

Comments are closed.